Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Tools & Techniques Analytical science, Cancer, Clinical trials

Writing Off Cancer

Meet the MasSpec Pen, a handheld mass spectrometry device with the potential to speed up accurate and intraoperative diagnosis of cancer. The pen – which releases a single water droplet onto suspected cancer tissue before drawing it back up for chemical analysis – was able to predict cancer with high sensitivity (96.4 percent), specificity (96.2 percent), and an overall accuracy of 96.3 percent (1).

Finding and removing the edges of cancerous tissue by sight alone is a particular challenge for surgeons, and successful resection of all the cancerous tissue clearly has huge health implications for the patient. The resulting demand for precise, accurate and rapid detection has already inspired one similar device: the electrosurgical iKnife, which uses rapid evaporative ionization mass spectrometry (see tas.txp.to/0215/PRECISIONMEDICINE). Both approaches use mass spectrometry, but the MasSpec Pen has one major difference: unlike the iKnife, which burns the target tissue and uses the smoke for analysis, it doesn’t destroy tissue as it analyzes it.

The MasSpec Pen was conceived by Livia Schiavinato Eberlin, Assistant Professor, Department of Chemistry, University of Texas at Austin – but for this small, yet seemingly mighty technology, it is only the beginning. 

“We are going to further validate the technology in my lab with larger sample sets and expand to other cancer types – then we’ll start testing in surgeries with our colleagues in the Texas Medical Center to compare our results with current results from clinical practice,” says Eberlin. “Then we should expand to larger clinical trials to properly evaluate if the technology can improve surgical treatment and patient care.” Eberlin and team hope to be able to trial it during operations within the next 12 months.

Eberlin says it is very rewarding to work on a project with such high potential impact. “Since working with R. Graham Cooks during my PhD, the last 10 years of my career have been dedicated to translational and clinical research, and I am excited about the recent development of the MasSpec Pen,” she says. “I am very passionate about the field, and specifically about developing mass spectrometry technology that can make a real difference in clinical practice. My amazing research team and I have been working extremely hard on this project. It is amazing to see what they have accomplished so quickly!”

Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Translational Scientist site. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

  1. J Zhang et al., “Nondestructive tissue analysis for ex vivo and in vivo cancer diagnosis using a handheld mass spectrometry system”, Sci Transl Med, 9, eaan3968 (2017).

About the Author

Joanna Cummings

A former library manager and storyteller, I have wanted to write for magazines since I was six years old, when I used to make my own out of foolscap paper and sellotape and distribute them to my family. Since getting my MSc in Publishing, I’ve worked as a freelance writer and content creator for both digital and print, writing on subjects such as fashion, food, tourism, photography – and the history of Roman toilets. Now I can be found working on The Analytical Scientist, finding the ‘human angle’ to cutting-edge science stories.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register